New data from the CDC reveals that the 2024 flu shot significantly reduced the risk of flu-related hospitalizations by 35% in high-risk individuals, including young children, older adults, and those with chronic health conditions. The findings, based on data from five South American countries, offer promising insight into the potential effectiveness of the upcoming Northern Hemisphere flu season.
The FDA has approved FluMist, a nasal spray flu vaccine, for at-home use, offering a convenient and accessible option for individuals ages 18 to 49. This approval expands on the existing use of FluMist for children and adolescents ages 2 to 17, allowing their caregivers to administer the spray. The move comes after clinical trials demonstrated the safety and effectiveness of self-administering the vaccine, making flu protection more accessible for a wider population.
Pfizer and BioNTech’s combined mRNA vaccine for influenza and COVID-19 has shown mixed results in a Phase 3 trial. While it met one of its primary immunogenicity objectives, it demonstrated lower responses against the influenza B strain compared to a licensed flu vaccine. The companies are evaluating adjustments to improve the vaccine’s effectiveness.
